Determination of esculentoside A in dog plasma by LC–MS/MS method: Application to pre-clinical pharmacokinetics

Guan, Xiaoduo; Chang, Huichao; Sun, Fanlu; Chen, Xiaohui; Zhang, Wen; Fan, Guorong

doi:10.1016/j.jpba.2012.09.002

Cited by 11 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…Then, a weight theoretically equivalent to 100 μg of EsA was digested completely using 10 mL acetic acid for 30 min at room temperature. The resultant supernatant was assayed for EsA concentration via high-performance liquid chromatography (Agilent 1100, Agilent Technologies, Inc., USA) after centrifuging at 14,000 rpm for 30 min . The experiment was conducted in triplicate.…”

Section: Methodsmentioning

confidence: 99%

“…The resultant supernatant was assayed for EsA concentration via highperformance liquid chromatography (Agilent 1100, Agilent Technologies, Inc., USA) after centrifuging at 14,000 rpm for 30 min. 32 The experiment was conducted in triplicate. The NP yield was calculated as follows The encapsulation efficiency (EE) was calculated as follows For procedure optimization, the volumes and concentrations of ALG solution, CaCl 2 solution, and CS solution; the pH of ALG and CS solutions; and the surfactant Tween 20 (0.5 mL) were adjusted to produce well-formed nanoparticles.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Chitosan/Alginate Nanoparticles with Sustained Release of Esculentoside A for Burn Wound Healing

Zhu

Shao

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Burn injury remains one of the most devastating burdens on global public health. The inflammation, caused by burn injury and transplantation of dermal scaffolds, often leads to delayed burn wound healing. Esculentoside A (EsA), with a strong anti-inflammatory capacity, is an available agent that might contribute to the treatment of burn wounds. However, the poor stability and toxicity of EsA limit its clinical application. In the present study, we constructed chitosan/alginate nanoparticles (EsA-CS/ALG-NPs) to improve sustainability and reduce toxicity followed by impregnation of the prepared EsA-CS/ALG-NPs into a collagen/chitosan scaffold (EsA-CS/ALG-NPs@CCS). The particle size, structural morphology, thermal properties, and chemical interaction of repaired nanoparticles were evaluated using the Nanometrics instrument, differential scanning calorimetry, transmission electron microscopy, and Fourier transform infrared spectroscopy, respectively. The hybrid EsA-CS/ALG-NPs@CCS was evaluated for physical characteristics, in vitro drug release, biocompatibility, and anti-inflammation capacity with RAW 264.7 cells and in vivo burn wound healing studies with SD rats. The results showed that we successfully constructed CS/ALG-NPs and optimized the preparation process to achieve the highest encapsulation efficiency. The hybrid EsA-CS/ALG-NPs@CCS, with reduced cytotoxicity and sustained release of EsA, could alleviate inflammation, decrease the ratio of M1 macrophages, and increase the proportion of M2 macrophages in vitro. It was demonstrated that 5 μg EsA CS/ALG-NPs@CCS not only reduces inflammatory cytokines secretion and inhibits M1 macrophages but also promotes the release of anti-inflammatory cytokines and activates M2 macrophages, thereby achieving accelerated and high-quality healing of burn wounds ultimately. In summary, our work suggests that the synergistic combination of EsA, nanoparticles, and scaffolds provided a promising strategy for treating burn injuries.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Chitosan/Alginate Nanoparticles with Sustained Release of Esculentoside A for Burn Wound Healing

Zhu

Shao

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…Moreover, Guan et al. developed an LC–MS/MS method for determination of esculentoside A in dog plasma. However, the pharmacokinetic study of other bioactive triterpenoids, such as esculentoside H, esculentoside T, esculentoside B, and phytolaccagenic acid of PA has not been reported yet.…”

Section: Introductionmentioning

confidence: 99%

Development of an ultra‐high‐performance liquid chromatography coupled with triple quadrupole mass spectrometry method for comparative pharmacokinetics of six triterpenoids in rat plasma and application to different forms of Phytolacca acinosa

Tao

Jiang

Cai

2020

J of Separation Science

View full text Add to dashboard Cite

Phytolacca acinosa is an herb for treatment of ascites and tumor. Two forms of P. acinosa, i.e. raw and vinegar-processed herb, have been used in clinic. However, pharmacokinetic difference between the two forms of P. acinosa has not been fully understood. Herein, a comparative pharmacokinetic method based on liquid chromatography with tandem mass spectrometry was developed for quantification of six bioactive triterpenoids, including esculentoside H, esculentoside T, esculentoside A, esculentoside B, phytolaccagenic acid, and phytolaccagenin in rat plasma after oral administration of different forms of P. acinosa. Separation was performed on an Acquity BEH C 18 column (1.7 µm, 2.1 mm × 50 mm). The method was validated over a linear range of 2.0-5000 ng/mL. Intraday and interday bias were within ±5%. Besides, all triterpenoids were stable in plasma during different storage conditions. The described method was successfully applied to a comparative pharmacokinetic study of raw and vinegar-processed P. acinosa in rats. Notably, double peak phenomenon for six triterpenoids of P. acinosa was observed for the first time. AUC 0→t and C max values of esculentoside H, esculentoside T, phytolaccagenic acid, and phytolaccagenin were significantly lower in vinegar-processed group than that of raw group, indicating the oral bioavailability of the four triterpenoids was decreased after vinegar processing. K E Y W O R D Sphytolacca acinosa, pharmacokinetics, traditional Chinese medicine 1248

show abstract

Integrating non‐targeted metabolomics and toxicology networks to study the mechanism of Esculentoside A‐induced hepatotoxicity in rats

Liu

et al. 2021

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Esculentoside A (EsA) is a kind of triterpenoid saponins from the root tuber of Phytolacca acinosa Roxb. It has extensive medicinal activity, such as antibacterial, anti-inflammatory, immune regulation, and cell proliferation inhibition. However, some researches suggested that EsA can cause hepatotoxicity, whose mechanism is not precise. To ensure the safety and reliability in the clinical use of Phytolacca acinosa Roxb., it is necessary to establish a rapid and accurate method to evaluate the toxicity, analyze and verify the toxicity mechanism of EsA. Therefore, this research explored the mechanism of hepatotoxicity induced by EsA in rats and analyzed endogenous metabolites' changes in rat plasma by combining network toxicology with non-targeted metabolomics. We obtained 58 critical targets of EsA induced hepatotoxicity in rats based on the strategy of network toxicology, including albumin, mitogen-activated protein kinase 1, Caspase-3, etc. Many important pathways were obtained by Kyoto Encyclopedia of Genes and Genomes enrichment analysis, such as HIF-1 signaling pathway, TNF signaling pathway, IL-17 signaling pathway, and other concerning pathways. Sixteen biomarkers, including 5-hydroxykynurenamine, N-acetylserotonin, palmitic acid, etc., were screened from rat plasma using Ultra-performance liquid chromatography coupled with quadrupole time of flight mass spectrometry (UPLC-Q-TOF/MS), mainly involve Glycerophospholipid metabolism, Tryptophan metabolism, and other metabolic pathways.Further analysis showed that EsA may induce liver injury by activating oxidative stress and energy metabolism disorders, triggering inflammation and apoptosis.

show abstract

Determination of esculentoside A in dog plasma by LC–MS/MS method: Application to pre-clinical pharmacokinetics

Cited by 11 publications

References 10 publications

Chitosan/Alginate Nanoparticles with Sustained Release of Esculentoside A for Burn Wound Healing

Chitosan/Alginate Nanoparticles with Sustained Release of Esculentoside A for Burn Wound Healing

Development of an ultra‐high‐performance liquid chromatography coupled with triple quadrupole mass spectrometry method for comparative pharmacokinetics of six triterpenoids in rat plasma and application to different forms of Phytolacca acinosa

Integrating non‐targeted metabolomics and toxicology networks to study the mechanism of Esculentoside A‐induced hepatotoxicity in rats

Contact Info

Product

Resources

About